Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 3/2008

01-03-2008 | Short Communication

The association between the IFIH1 locus and type 1 diabetes

Authors: H.-Q. Qu, L. Marchand, R. Grabs, C. Polychronakos

Published in: Diabetologia | Issue 3/2008

Login to get access

Abstract

Aims/hypothesis

We set out to validate a recently reported type 1 diabetes association from the IFIH1 gene variation in an independent cohort from a population of mixed European descent.

Methods

We genotyped five single-nucleotide polymorphisms in the IFIH1 locus, i.e. rs2111485, rs1990760, rs3747517, rs17783344 and rs984971589, in 589 type 1 diabetes nuclear family trios (1,767 individuals).

Results

This study independently replicated the reported genetic association using a family-based approach.

Conclusions/interpretation

The reported type 1 diabetes association is from a linkage disequilibrium region including three candidate genes, i.e. FAP, IFIH1 and GCA. Further variant discovery and fine mapping could help clarify a novel type 1 diabetes mechanism.
Appendix
Available only for authorised users
Literature
1.
Smyth DJ, Cooper JD, Bailey R et al (2006) A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 38:617–619PubMedCrossRef
2.
Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB (2002) mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci U S A 99:637–642PubMedCrossRef
3.
Kato H, Takeuchi O, Sato S et al (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101–105PubMedCrossRef
4.
van der Werf N, Kroese FG, Rozing J, Hillebrands JL (2007) Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 23:169–183PubMedCrossRef
5.
6.
Haverkos HW, Battula N, Drotman DP, Rennert OM (2003) Enteroviruses and type 1 diabetes mellitus. Biomed Pharmacother 57:379–385PubMedCrossRef
7.
Qu H-Q, Marchand L, Grabs R, Polychronakos C (2007) The IRF5 polymorphism in type 1 diabetes. J Med Genet 44:670–672PubMedCrossRef
8.
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265PubMedCrossRef
9.
Horvath S, Xu X, Laird NM (2001) The family based association test method: strategies for studying general genotype–phenotype associations. Eur J Hum Genet 9:301–306PubMedCrossRef
10.
Dudbridge F (2003) Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25:115–121PubMedCrossRef
11.
Fassnacht M, Lee J, Milazzo C et al (2005) Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clin Cancer Res 11:5566–5571PubMedCrossRef
12.
Boyhan A, Casimir CM, French JK, Teahan CG, Segal AW (1992) Molecular cloning and characterization of grancalcin, a novel EF-hand calcium-binding protein abundant in neutrophils and monocytes. J Biol Chem 267:2928–2933PubMed
Metadata
Title
The association between the IFIH1 locus and type 1 diabetes
Authors
H.-Q. Qu
L. Marchand
R. Grabs
C. Polychronakos
Publication date
01-03-2008
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2008
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0895-6

Other articles of this Issue 3/2008

Diabetologia 3/2008 Go to the issue

Erratum

Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus

Article

Pre-morbid intelligence, the metabolic syndrome and mortality: the Vietnam Experience Study

Article

Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients

For Debate

Exercise: the brittle cornerstone of type 2 diabetes treatment

For Debate

Fatty acid-induced mitochondrial uncoupling in adipocytes is not a promising target for treatment of insulin resistance unless adipocyte oxidative capacity is increased

Article

Presence of functional cannabinoid receptors in human endocrine pancreas
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits